Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortés
Topics & Concepts
MedicinePembrolizumabInternal medicineCapecitabineOncologyEribulinMetastatic breast cancerBreast cancerTriple-negative breast cancerTaxaneVinorelbineGemcitabineChemotherapyAnthracyclineCancerClinical endpointClinical trialColorectal cancerImmunotherapyCisplatinCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesBreast Cancer Treatment Studies